Common Stock, $.01 par value
- Symbol
- DCTH
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 2.02, 9.01 · 8-K
Delcath Systems, Inc.
DCTHNASDAQEQUITYCurrent
Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On November 9, 2026, Delcath Systems, Inc. (“Delcath”) issued a press release announcing financial results and business highlights for the quarter ended September 30, 2026 (the “Press Release”). A copy of the press release is furnished pursuant to Item 2.02 as Exhibit 99.1 hereto and is incorporated herein by reference.…
Press release in this filing
Delcath Systems Reports Third Quarter 2026 Results and Business Highlights →Company context
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company's proprietary products, HEPZATO KIT™ (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT® Hepatic Delivery System (HDS) for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure.
Current securities
Registered securities in this filing
DELCATH SYSTEMS, INC. · 8-K · Filed 2026-11-09
Disclosure sections
Item 2.02Item 2.02 - Results of Operations
Item 2.02
Results of Operations and Financial Condition.
On November 9, 2026, Delcath Systems, Inc. (“Delcath”) issued a press release announcing financial results and business highlights for the quarter ended September 30, 2026 (the “Press Release”). A copy of the press release is furnished pursuant to Item 2.02 as Exhibit 99.1 hereto and is incorporated herein by reference.
The information contained in this Current Report on Form 8-K, including the Press Release, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the Press Release shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission by Delcath whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Filed exhibits (1)
Exhibit 99.1 Delcath Systems Reports Third Quarter 2026 Results and Business Highlights Increases 2026 Revenue Guidance to a Range of $115 million to $117 million Conference Call Today at 8:30 a.m. Eastern Time QUEENSBURY, NY - November 9, 2026, Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results and business highlights for the third quarter ended September 30, 2026. Third Quarter 2026 Financial Results • Total revenue of $35.1 million, compared with $20.6 million in the third quarter of 2025 ◦ HEPZATO KIT™ revenue of $32.7 million, compared to $19.3 million in the third quarter of 2025 ◦ CHEMOSAT® revenue of $2.4 million, compared to $1.3 million in the third quarter of 2025 • Gross margins of 89%, compared to 87% in the third quarter of 2025 • Net income of $7.0 million, compared to $0.8 million in the third quarter of 2025 • Non-GAAP adjusted EBITDA of $11.5 million, compared to $5.3 million in the third quarter of 2025 • Cash provided by operations of $8.2 million in the quarter; compared to $4.8 million in the third quarter of 2025 • Cash and i…
Open exhibit ↗